Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a rare and poorly reported complication of Waldenstr€ om macroglobulinaemia (WM). We performed a retrospective study of 77 WM patients with biopsy-proven transformation to DLBCL. The median time from WM diagnosis to HT was 4Á6 years and 16 patients (21%) had never been treated for WM. At HT, extranodal sites were observed in 91% of patients with a rather high incidence of central nervous system, cutaneous or testicular involvement. Fluorodeoxyglucose-positron emission tomography was performed in half of the patients and the median maximum standardized uptake value was 15 for transformed disease. More than 80% of cases with available data for assessment by the Hans' algorithm harboured a non-germinal centre B-cell phenotype. First-line treatment for transformation consisted of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)-like regimen in 85% of patients. The overall response rate after first-line treatment was 61% and the median overall survival was only 16 months for the entire cohort. Time to transformation above 5 years (P = 0Á0004) and elevated LDH (P = 0Á02) were associated with worse outcome. Based on these findings, HT should be considered and lead to a biopsy in WM patients presenting with extranodal involvement, elevated LDH and constitutional symptoms. The optimal therapeutic approaches remain to be defined.
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Waldenstr€ om macroglobulinaemia (WM) is a rare B-cell lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration and the presence of a serum monoclonal IgM paraprotein (Swerdlow et al, 2008) . Its clinical course is variable and a substantial proportion of patients are asymptomatic at diagnosis. Symptoms seen at progression or already present at diagnosis are related to tumour infiltration, monoclonal M-component activity (hyperviscosity syndrome, IgM-related neuropathy, cryoglobulinaemia, cold agglutinin haemolytic anaemia) and/or deposition in organs. Despite recent therapeutic advances over the last decade, WM still remains an incurable disease. Relapses are common in WM patients and histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) may occur, although it is a rare event.
HT refers to the development of a high-grade lymphoma in patients with indolent lymphoma and is usually characterized by an aggressive clinical course and a poor prognosis. HT is well described in the natural history of patients with follicular lymphoma (transformed follicular lymphoma) and chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (Richter syndrome) (Casulo et al, 2015; Rossi & Gaidano, 2016) . HT has been reported in WM but data on clinicopathological characteristics and outcome of patients with transformed WM are scarce and rely on case reports or small patient series (Lin et al, 2003; Leleu et al, 2009; Owen et al, 2011; Leblond et al, 2013) .
The purpose of this large multicentre retrospective study was to describe clinical and biological features, therapeutic approaches, clinical outcomes and prognostic factors of patients with transformed WM.
Methods

Study population
We retrospectively searched the databases of French and Belgian centres for patients older than 18 years diagnosed with WM and a concurrent or sequential diagnosis of DLBCL between 1995 and 2016. Nineteen centres belonging to the French Innovative Leukemia Organization (FILO) group participated in this study. Patients with a diagnosis of indolent lymphoma other than WM were excluded. The diagnosis of WM was based on criteria established in the Second International Workshop on WM (Owen et al, 2003) . A tissue biopsy was required for HT documentation. The diagnosis was made or confirmed for the majority of the cases by an expert haematopathologist from the Lymphopath network, a systematic review process of all newly diagnosed lymphoma cases in France sponsored by the French National Cancer Agency. This retrospective study was conducted in accordance with the Declaration of Helsinki and was approved by the French regulatory agencies [CCTIRS (Advisory Committee for Data Processing in Health Research), number 16-009 and CNIL (National Commission for Data Protection and Liberties), number 916052].
Assessments of patients and disease included, at both time of WM diagnosis and HT, age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), presence of B symptoms, presence of lymphadenopathy, splenomegaly and/ or hepatomegaly, complete blood counts, serum monoclonal IgM, serum creatinine, serum albumin, serum lactate dehydrogenase (LDH) and B2-microglobulin levels. Cytogenetic data and the presence of the MYD88 L265P mutation were collected at time of WM diagnosis and HT when available. For DLBCL, extranodal localizations were listed and Ann Arbor stage was reported. Prognostic scores were calculated for patients with available data using the International Prognostic Scoring System for WM (IPSSWM) and the International Prognostic Index (IPI) for HT (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993; Morel et al, 2009) . The germinal centre (GC) or non-GC phenotype of HT was determined from immunohistochemical data using the algorithm proposed by Hans et al (2004) . Number of lines of therapy, type and response to treatment for WM and for DLBCL were retrieved from patient files. Response assessment for WM was made according to criteria updated at the Sixth International Workshop on WM . For DLBCL, 2007 Cheson response criteria were used if a positron emission tomography (PET)-scan was performed and 1999 Cheson criteria if not (Cheson et al, 2007) .
Statistical analysis
Quantitative variables were expressed as median and range and qualitative variables as number and percentages. The time to transformation was defined as the time between the diagnosis of WM and the diagnosis of DLBCL. Progression-free survival (PFS) and overall survival (OS) from HT were defined as the time from diagnosis of HT until progression and death from any cause or last follow-up and death or last follow-up, respectively. Survival curves were plotted using the Kaplan-Meier method. Survival comparisons were performed using the log-rank test. Multivariate analyses using the Cox proportional hazard model were conducted to investigate the factors independently related to PFS and OS. Factors with a P-value less than 0Á10 by bivariate analyses were proposed in the model. The model was systematically adjusted for age and sex. P-values < 0Á05 were considered to indicate statistical significance. Statistical analyses were carried out using SAS 9Á4 (SAS Institute, Cary, NC, USA).
Results
Patients' characteristics at WM diagnosis
This study analysed 77 patients with transformed WM, including 11 patients (14%) with simultaneous diagnosis of WM and DLBCL. The patients' characteristics at time of WM diagnosis are summarized in Table I . Fifty patients (65%) were male and the median age at WM diagnosis was 66 years (32-85). Thirteen patients (17%) had a previous diagnosis of monoclonal gammopathy of undetermined significance and a family history of haematological malignancy was found in 9 patients (12%). Twenty-nine per cent of patients presented lymphadenopathy and 21% splenomegaly. The median level of serum monoclonal IgM was 22 g/l (2Á3-66Á7). According to the IPSSWM when available, 20 patients (41%) were classified as low-risk, 19 (40%) as intermediaterisk and 9 (19%) as high-risk. Cytogenetic data (karyotype +/À fluorescence in situ hybridisation, FISH) were available for 23 patients: deletion of chromosome 6q and trisomy 4 were found in 35% and 31% of cases respectively, deletion of chromosome 17p was present in 25% and a complex karyotype in 45%. The MYD88 L265P gene mutation was detected in each of the 5 cases tested.
Sixteen patients (21%) did not receive any treatment for WM until the diagnosis of HT. The median number of lines of therapy for WM was 1 (0-6), including chlorambucil in 66% of cases, nucleoside analogues in 49%, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) +/À rituximab in 16%, RCD (rituximab, cyclophosphamide, dexamethasone) in 15%, bendamustine +/À rituximab in 13% and proteasome inhibitor in 5%. Overall, 33 patients (54%) had received rituximab for WM at some point before HT.
Patients' characteristics at HT
The median time from WM diagnosis to HT was 4Á6 years [95% confidence interval (CI); 1Á4-8Á9]. The patients' characteristics at HT are summarized in Table II . The median age at HT was 71 years (33-89). Forty patients (54%) had an altered ECOG PS (≥2) and B symptoms were found in half of cases. Tumour mass larger than 5 cm and 10 cm were found in 48% and 18% of patients respectively. Extranodal involvement was present in 91% of patients. The most common involved extranodal sites were bone marrow (18%), bone (14%), spleen (14%), central nervous system (CNS: 13%, brain parenchyma in 7 patients and leptomeningitis in 3), pleura (13%), skin (12%), liver (8%), soft tissues (8%) and/or ascitis (5%).
The median serum IgM level was 7Á2 g/l (0-56). Thirtythree patients (46%) had anaemia with a haemoglobin concentration less than 100 g/l and 18 (25%) had thrombocytopenia with a platelet count less than 100 9 10 9 / l. Abnormal circulating lymphoid cells were detected in 11 patients (17%). Serum LDH level and ß2-microglobulin were elevated in 72% and 77% of cases respectively. Computed tomography (CT) scan and fluorodeoxyglucose-positron emission tomography (FDG-PET) were performed in 68 (88%) and 37 (48%) patients respectively. Standardized uptake values (SUVs) (n = 24) ranged from 3Á8 to 38, with a median of 15 and a mean of 16. Seventy-one per cent of patients presented with a highest SUVmax above 10 and it was above 17 in 50%. Based on the site of biopsy and imaging results (CT-scan and/or FDG-PET), 84% of patients had advanced Ann Arbor stage III or IV disease.
When the transformed disease was limited to a single site (13%), it was mainly skin involvement. The International Prognostic Index (IPI) score was high-intermediate in 36% of cases and high in 40%.
Pathological findings at HT
Transformation into high-grade lymphoma was confirmed on lymph node tissue in 30 patients, bone marrow sample in 14, skin biopsy in 9, brain parenchyma biopsy in 7, soft tissues in 6, testis in 3, pleura in 3, bone in 3 and kidney in 2. Histology, required for the diagnosis of transformation, was concordant with DLBCL subtype for all the cases, with 2 cases reported as B-cell lymphoma, intermediate between DLBCL and Burkitt lymphoma. By immunohistochemistry, cells were positive for CD10 in 10% of cases (n = 5/52), BCL6 in 46% (n = 16/35) and MUM1 in 84% (n = 21/25). According to the Hans' algorithm (Hans et al, 2004) , 82% of cases harboured a non-germinal centre B-cell phenotype (n = 27/33). BCL2 was expressed in 86% (n = 37/43) and MYC in 57% (n = 8/14). In situ hybridization for EpsteinBarr virus (EBV)-encoded small RNA (EBER) was negative in 25 of 27 informative cases (93%). The median Ki67 expression, available for 42 patients, was 80% (30-100). Immunoglobulin light chain expression (9 kappa and 4 lambda) was similar to the isotype of the serum monoclonal component for the 13 tested cases. Cytogenetic data were available for only 10 patients: a complex karyotype was found in 90% of cases and deletion of chromosome 17p in 30%. MYC rearrangement was detected by FISH in 38% (n = 3/8). The MYD88 L265P gene mutation was found in the 2 cases tested.
Therapy for HT
First-line treatments are detailed in Table II . The median number of lines of therapy given for HT was 1 (0-5). Five patients did not receive any treatment. First-line treatment for HT consisted of a CHOP-like regimen +/À rituximab in 61 patients (85%). Six patients (8%) received the DHAP (dexamethasone, cytarabine, cisplatin) regimen and 3 (4%) were treated with GEMOX (gemzar, oxaliplatin) due to cerebral involvement and/or previous CHOP-exposure. Rituximab was part of the first-line treatment for HT in 60 patients (83%). Thirteen patients underwent stem cell transplantation (SCT), including 11 autologous SCT and 3 allogeneic SCT (one patient allografted after autologous SCT failure). SCT was performed as part of first-line treatment strategy in 10 patients. The characteristics of transplanted patients, therapies before SCT, conditioning regimens and outcomes are depicted in Table SI. The overall response rate after first-line treatment for HT was 61% (40 patients out of 66 evaluable for response), including 32 patients (48%) achieving a complete response (CR) and 8 (13%) a partial response (PR). Stable disease (n = 5) or progression (n = 21) was observed in 39%. In univariate analysis, the only factor associated with a higher likelihood of response was a time to transformation of less than 5 years (P = 0Á04). Common salvage treatments for DLBCL were used for second-line treatment and included DHAP regimen for 10 patients, GEMOX for 6, ifosfamide-etoposide +/À carboplatin or mitoxantrone for 6 and bendamustine for 2. The overall response rate to second-line treatment was 48%.
Survival analysis
The median follow-up for all patients was 7Á3 years (0Á2À33Á7) after the diagnosis of WM and 11 months (0Á3-163) after HT. The median OS from the time of the diagnosis of WM was 9 years (95% CI; 7Á5-11). The median PFS and OS after HT were 9 months (95% CI; 6-18) and 16 months (95% CI; 10-33) respectively (Fig 1) . There were no statistical differences in terms of PFS and OS between patients with synchronous WM and DLBCL and patients with sequential diagnosis (P = 0Á22 for PFS and P = 0Á32 for OS). Among responders, the median duration of OS was not reached for patients who received SCT (n = 10) whereas it was 4Á5 years for patients who did not proceed to SCT (n = 30) (P = 0Á33, Figure S1 ). At the time of the analysis, 50 patients (65%) have died. The majority of deaths were attributed to progressive disease (76%) or infections (12%). Other causes of deaths included lung cancer (n = 1), acute myeloid leukaemia (n = 2) and unknown cause (n = 3).
Prognostic factors
In univariate analysis, variables that were specifically associated with shorter PFS after HT were prior rituximab exposure (P = 0Á02), time to transformation ≥5 years (P = 0Á01), elevated LDH (P = 0Á01) and absence of response (no CR/ PR) to treatment (P < 0Á0001). Factors that predicted poor OS were 2 or more lines of treatment for WM (P = 0Á04), prior rituximab exposure (P = 0Á04), time to transformation ≥5 years (P = 0Á004), elevated LDH (P = 0Á02) and absence of response (no CR/PR) to treatment (P < 0Á0001) (Table III) . Kaplan-Meier OS estimates are shown in Fig 2. Sex, age >70 years, ECOG PS, serum IgM level at diagnosis of WM and at HT, light chain isotype, IPSSWM score, previous exposure to purine analogues or to alkylating agents, haemoglobin level <100 g/l, platelet count <100 9 10 9 /l, leucocyte count <4 9 10 9 /l, albumin level <35 g/l, GC/non-GC phenotype, Ann Arbor stage were not statistically significant in univariate analysis for PFS and OS. In multivariate analysis, independent factors of PFS and OS were time to transformation ≥5 years (Hazard ratio (HR) = 2Á1, 95% CI; 1Á2-3Á8, P = 0Á01 for PFS, HR = 3Á2, 95% CI; 1Á7-6Á2, P = 0Á0004 for OS) and elevated LDH (HR = 2Á5, 95% CI; 1Á2-5Á3, P = 0Á02 for PFS, HR = 2Á7, 95% CI; 1Á2-6Á2, P = 0Á02 for OS) (Table IV) .
Discussion
Histological transformation to DLBCL is a rare complication that may occur in patients with WM. The cumulative incidence of transformation ranges from 2Á4% at 10 years in a retrospective study of untreated and treated WM patients to 8-11% at 6 years in a prospective randomized study including symptomatic patients in need for treatment Castillo et al, 2016) . The available literature regarding transformed WM is limited to case reports; the largest series report monocentric experiences and comprise 12 cases in the study by Lin et al (2003) and 20 cases in the more recently published one by Castillo et al (2016) . Moreover, pathological heterogeneity has been reported in aggressive lymphomas evolving from low-grade B-cell lymphomas. The most frequent histology subtype is DLBCL but B-cell lymphoma intermediate between DLBCL and Burkitt lymphoma, lymphoblastic and blastoid lymphomas have been described in follicular lymphoma and about 10% of Richter syndrome are classified as Hodgkin variant. WM is no exception to this rule, with some cases recognized as EBV-associated DLBCL, T-cell lymphoma, anaplastic large-cell lymphoma and plasma cell proliferation (Hamada et al, 1999; Owen et al, 2011) . In order to minimize weaknesses already inherent in the nature of a retrospective analysis, we used stringent inclusion criteria for the diagnosis of transformation by restricting our analysis to both biopsy-proven transformation and DLBCL histological subtype. This large retrospective study provides details on extranodal involvement, novel information on a potential role of FDG-PET in transformed WM patients and prognostic factors. Transformed WM was first described by Wood and Frenkel (1967) , who reported the emergence of a lymphoblastic lymphoma in a patient with WM, and McCallister et al (1967) , who reported two cases of anaplastic sarcoma. Other case reports described the development of 'reticulum cell sarcoma' and 'immunoblastic sarcoma' in WM patients (Osterburg & Rausing, 1970; MacKenzie & Fudenberg, 1972; Skarin & Long, 1978; Choi et al, 1979; Leonhard et al, 1980) . Common characteristics were a decrease in serum IgM levels and poor outcome at time of HT. This could be explained by the fact that the majority of patients were responding to last treatment for WM before HT and/or a phenomenon of dedifferentiation in which the aggressive clone losses the ability to secrete IgM. Based on this finding and the expression of the same light chain isotype in WM and DLBCL, the occurrence of an aggressive lymphoma in WM was mainly described as a transformation and not as a new malignancy in the first reports. In the present study, we were not able to assess the clonal relationship between the original WM and DLBCL but 100% of the tested cases (n = 13) had concordant light chain expression. EBV infection is sometimes suggested to play a role in transformed lymphomas. EBV does not seem to be involved in the transformation of WM given that the vast majority of our tested cases were negative for in situ hybridization of EBERs, as the case in the study by Lin et al (2003) with 8 negative cases out of 8 tested. Study of paired biopsy specimens of WM and subsequent DLBCL would help the understanding of pathogenesis of transformed WM.
Patients with transformed WM presented high IPI scores in the vast majority of cases. The high frequency of extranodal involvement we observed was consistent with previous reports of transformed WM showing rates of 84-100% of extranodal disease (Lin et al, 2003; Castillo et al, 2016) . Bone marrow was the main localization of extranodal DLBCL in our study, concerning 18% of cases. Interestingly, among other sites of extranodal involvement, CNS (14%), skin (12%) and, to a lesser extent, testis (4%) involvement were quite common. It is notable that the 'de novo' counterpart of those localizations, i.e. primary CNS lymphoma, cutaneous DLBCL of leg-type and primary testicular DLBCL, are strongly associated with MYD88 mutations, with frequencies ranging from 59% to 79% (Kraan et al, 2013; Pham-Ledard et al, 2014; Braggio et al, 2015) . A recent study of 213 patients with de novo DLBCL has shown an association between MYD88 L265P mutations and DLBCL of activated B-cell like (ABC) lymphoma origin, extranodal involvement and poor outcome (Rovira et al, 2016) , characteristics found in our study. Regarding extranodal involvement in DLBCL, MYD88 L265P mutation, a hallmark of WM, and CD79B mutations occur preferentially in immune-privileged site-associated DLBCL (CNS and testis). These mutations are presumed to play a role in the pathogenesis of the outgrowth of the tumour cells within these sites. We can hypothesize a similar role in the pathogenesis of transformed WM.
This high rate of extranodal involvement at HT is in contrast to what is reported with WM, where tissue infiltration other than bone marrow, lymphadenopathy and hepatosplenomegaly is rare. An entity of 'extramedullary WM' has been described with a frequency of 4Á4% (43 patients out of 985), occurring mainly after treatment (Banwait et al, 2015) . The implication of CXCR4, which is mutated in about 30-40% of WM patients and known to play a role in cell trafficking regulation and homing, should be investigated in this setting (Treon et al, 2014) . Of note, extramedullary disease did not confer a worse outcome in this study of nontransformed WM. Considering those data, a biopsy should be performed in a patient with WM presenting extramedullary and extranodal disease. FDG-PET was performed in about half of the patients in our study and SUVs were available for 24 patients. The usefulness of FDG-PET to detect HT in other indolent lymphomas and to guide the site of biopsy has been widely studied. Higher SUVs are correlated with more aggressive histology (Noy et al, 2009 ). However, data concerning the value of FDG-PET in the patient population of WM are scarce. In a series of 35 patients, 77% had positivity on FDG-PET with a moderate FDG avidity, SUVmax not exceeding 7Á7 (Banwait et al, 2011) . In the present study, SUVs ranged from 3Á8 to 38 with a median of 15 and a mean of 16. FDG-PET could be a potential tool in WM but larger studies are required to assess its usefulness for the detection of HT.
Prognostic factors identifying patients with WM at risk of transformation are needed. The use of purine analogues has been suggested to be associated with an increased risk of HT and development of myelodysplasia or acute myeloid leukaemia in some studies (Leleu et al, 2009 ). In contrast, a large randomized trial comparing fludarabine and chlorambucil did not find any differences in term of incidence of transformation . The study by Lin et al (2003) also failed to identify clinical and biological risk factors associated with the development of DLBCL. In this retrospective analysis, we were not able to compare our cohort to WM patients without HT but we looked for factors predicting response and survival at time of transformation. Time to transformation more than 5 years and elevated LDH are the two factors that independently predict for shorter survival. Age, performance status, Ann Arbor stage and number of extranodal sites, characteristics that define the IPI with LDH level, were not significant. Time to HT longer than 5 years could reflect previous exposure to therapy and/or immunological impairment related to the disease. Prolonged time to transformation had already been associated with shorter survival in Richter syndrome (Tsimberidou et al, 2006) . A simple prognostic score could be designed with these two factors and should be validated in an independent cohort of patients with transformed WM.
Despite the retrospective nature of the study, first-line treatments at HT were quite uniform with the majority of patients being treated by R-CHOP chemoimmunotherapy, similarly to de novo DLBCL. The overall response rate was in the range of what has been described in transformed WM but duration of response and OS were short. The prognosis of transformed indolent lymphomas is historically poor but the addition of rituximab and the use of high-dose therapy with SCT helped to improve these results (Ban-Hoefen et al, 2013; Kuruvilla et al, 2015) . In our series, 83% of patients received rituximab and 13 patients underwent SCT, including 10 in first complete remission, with a median OS not reached as compared to 4Á5 years for the patients who had responded but had not received transplantation. The difference was not statistically significant but the number of patients is small. Larger studies are needed to confirm these findings.
Our study has some limitations. Despite the large number of transformed WM patients included, this is a retrospective study over a long period, leading to missing data, particularly on pathological data and mutational analysis, and it does not extend and deepen our knowledge of the pathology of the transformation. However, it identifies some informative clinical aspects. Similarly to transformation occurring in other types of indolent lymphomas, HT in patients with WM should be considered at any time during the course of the disease in the case of altered performance status, constitutional symptoms, bulky disease, elevated LDH and extranodal involvement, particularly MYD88-associated sites, such as CNS, skin and testis. Diagnosis of transformation relies on histological examination of tissue biopsy whose site can be guided by FDG-PET. Most patients were treated with chemoimmunotherapy but survival from the time of the transformation remains short. Further studies are needed to define risk factors for developing DLBCL, molecular characteristics of transformed WM and the optimal therapeutic approaches.
